Drug Trial Radar · NCT07469891
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Apr 29, 2026
Primary completion
Apr 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- Prelude Therapeutics IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Mar 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE\[s\]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).
Conditions
- Polycythemia Vera (PV)
- Myelofibrosis (MF)
- Myeloproliferative Neoplasms (MPNs)
- Post-Polycythemia Vera Myelofibrosis
- Post-Essential Thrombocythemia Myelofibrosis
- Primary Myelofibrosis (PMF)
Interventions
PRT12396Drug
PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT) of PRT12396Time frame: Through cycle 1 (4 weeks)
- Incidence and severity of Adverse eventsTime frame: Through study completion, an average of 2 years
- Adverse Events Leading to Dose Modifications or DiscontinuationTime frame: Through study completion, an average of 2 years
- Maximum tolerated dose (MTD) and Recommended Dose(s) for Expansion (RDE[s]) of PRT12396Time frame: Through study completion, an average of 2 years
Locations
22 sites in 5 countries. Site status is shown where the registry gives one.
UCLA Ronald Reagan Medical Center
Los Angeles, California · Recruiting
University of California, Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Colorado Blood Cancer Institute
Denver, Colorado · Recruiting
BRCR Global - Coral Springs
Coral Springs, Florida · Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
START Midwest, LLC
Grand Rapids, Michigan · Recruiting
Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office
Philadelphia, Pennsylvania · Recruiting
Tennessee Oncology, PLLC - Investigational Drug Services
Nashville, Tennessee · Recruiting
Tristar BMT
Nashville, Tennessee · Recruiting
The University of Texas, MD Anderson Cancer Center
Houston, Texas · Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
Monash Health, Monash Medical Centre
Clayton, Victoria, Australia · Recruiting
One Clinical Research
Nedlands, Western Australia, Australia · Recruiting
Nice University Medicâl Center (CHU Nice, Hôpital Archet 1)
Nice, France · Recruiting
Saint-Louis Hospital
Paris, France · Recruiting
Oncopole Claudius Regaud
Toulouse, France · Recruiting
Azienda Ospedaliero Universitaria Careggi
Florence, Italy · Recruiting
Hospital Clinic de Barcelona
Barcelona, Spain · Recruiting
Hospital Universitario Ramon y Cajal
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Clínico Universitario de Valencia
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.